The relatively new drug denosumab (Xgeva) reduces bone complications of advanced breast cancer more effectively than another osteoporosis drug, zoledronic acid (Zometa), according to new research. Zoledronic acid belongs to a class of drugs known as bisphosphonates, which help delay bone complications such as fractures, spinal cord compression and bone pain. But zoledronic acid has been linked with kidney toxicity and other reactions. Denosumab, a newer drug called a monoclonal antibody, is superior to zoledronic acid in reducing skeletal problems and better tolerated, the study found.
